Metabolic reprogramming-driven stratification and therapeutic targeting in lung adenocarcinoma: implications for prognosis and personalized treatment

This study presents a novel MRPs system that captures LUAD metabolic and immune heterogeneity and surpasses traditional clinicopathologic parameters in prognostic performance. WARS2 emerges as a functional driver and therapeutic target. These findings offer a comprehensive framework for metabolic-state-based stratification and personalized treatment strategies in LUAD.